Positive cytokeratin 19 expression promotes poor outcomes in HCCSeptember 18, 2021Hepatocellular Carcinoma
Treatment-related adverse events correlate with improved outcomes in HCC patients on immune checkpoint inhibitor therapySeptember 18, 2021Hepatocellular Carcinoma
Addition of raltitrixed extended overall survival in hepatocellular carcinomaSeptember 18, 2021Hepatocellular Carcinoma
Higher postoperative CONUT scores predict poor outcomes in small HCC after liver resectionSeptember 18, 2021Hepatocellular Carcinoma
Hepatic resection shows superior survival for resectable caudate HCCSeptember 18, 2021Hepatocellular Carcinoma
Adverse events create substantial healthcare costs in hepatocellular carcinomaSeptember 18, 2021Hepatocellular Carcinoma
Combination arsenic emulsion in TACE and apatinib benefits advanced HCC patientsSeptember 18, 2021Hepatocellular Carcinoma
New predictive markers for risk of HCC in cirrhotic chronic hepatitis BSeptember 18, 2021Hepatocellular Carcinoma
Adding pembrolizumab shows promise for treating unresectable HCCSeptember 18, 2021Hepatocellular Carcinoma
Antiviral Therapy Improves Hepatocellular Cancer SurvivalSeptember 3, 2021Hepatocellular CarcinomaHepatitisInfectious Diseases
Bone resorption inhibitors extend OS in castration-resistant prostate cancerAugust 29, 2021Hepatocellular Carcinoma
Prostate cancer: PDE-5 inhibitor use linked to survival benefitAugust 29, 2021Hepatocellular Carcinoma
